Post-insult valproate treatment potentially improved functional recovery in patients with acute middle cerebral artery infarction

American Journal of Translational Research

Volumn 6, Issue 6, 2014, Pages 820-830

  Lee, Jiunn Tay ^a   Chou, Chung Hsing ^a   Cho, Nai Yu ^a   Sung, Yueh Feng ^a   Yang, Fu Chi ^a   Chen, Cheng Yu ^b   Lai, Yu Hua ^a,c   Chiang, Chun I ^a,d   Chu, Chi Ming ^e   Lin, Jiann Chyun ^a   Hsu, Yaw Don ^a   Hong, Jau Shyong ^f   Peng, Giia Sheun ^a   Chuang, De Maw ^g  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Tri Service General Hospital Penghu Branch   (Taiwan)

^d HUALIEN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^f NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^g NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Ischemic stroke; Neuroprotection; Stroke outcome; Valproate

Indexed keywords

VALPROIC ACID;

AGED; ARTICLE; BARTHEL INDEX; BLOOD CELL COUNT; BLOOD PRESSURE; BODY MASS; BRAIN FUNCTION; BRAIN ISCHEMIA; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG BLOOD LEVEL; ELECTROCARDIOGRAPHY; ELECTROLYTE BLOOD LEVEL; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; LIVER FUNCTION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE;

EID: 84912097781     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Garcia JH, Yoshida Y, Chen H, Li Y, Zhang ZG, Lian J, Chen S, Chopp M. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. Am J Pathol 1993; 142: 623-35.
2. Hossmann KA. Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994; 36: 557-65.
3. Tissue plasminogen activator for acute isch-emic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-7.
4. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfeld K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2013; 44: 870-947.
5. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotec-tion for ischemic stroke: two decades of success and failure. NeuroRx 2004; 1: 36-45.
6. O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol 2006; 59: 467-77.
7. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, Hurn P, Liebeskind DS, Nogueira RG, Saver JL; STAIR VII Consortium. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke 2011; 42: 2645-50.
8. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH, Group S. Update of the stroke therapy academic industry roundta-ble preclinical recommendations. Stroke 2009; 40: 2244-50.
9. Johannessen CU. Mechanisms of action of val-proate: a commentatory. Neurochem Int 2000; 37: 103-10.
10. Tunnicliff G. Actions of sodium valproate on the central nervous system. J Physiol Pharmacol 1999; 50: 347-65.
11. Henry TR. The history of valproate in clinical neuroscience. Psychopharmacol Bull 2003; 37 Suppl 2: 5-16.
12. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714.
13. Wang ZF, Fessler EB, Chuang DM. Benefcial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacol Sin 2011; 32: 1433-45.
14. Chiu CT, Wang Z, Hunsberger JG, Chuang DM. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 2013; 65: 105-42.
15. Fessler EB, Chibane FL, Wang Z, Chuang DM. Potential roles of HDAC inhibitors in mitigating ischemia-induced brain damage and facilitating endogenous regeneration and recovery. Curr Pharm Des 2013; 19: 5105-20.
16. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 2004; 89: 1358-67.
17. Wang Z, Tsai LK, Munasinghe J, Leng Y, Fessler EB, Chibane F, Leeds P, Chuang DM. Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recov ery in a rat model of ischemic stroke. Stroke 2012; 43: 2430-6.
18. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-infammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007; 321: 892-901.
19. Wang Z, Leng Y, Tsai LK, Leeds P, Chuang DM. Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab 2011; 31: 52-7.
20. Sinn DI, Kim SJ, Chu K, Jung KH, Lee ST, Song EC, Kim JM, Park DK, Kun Lee S, Kim M, Roh JK. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacety-lase inhibition and transcriptional activation. Neurobiol Dis 2007; 26: 464-72.
21. Pantano P, Caramia F, Bozzao L, Dieler C, von Kummer R. Delayed increase in infarct volume after cerebral ischemia: correlations with th-rombolytic treatment and clinical outcome. Stroke 1999; 30: 502-7.
22. Markus R, Reutens DC, Kazui S, Read S, Wright P, Chambers BR, Sachinidis JI, Tochon-Danguy HJ, Donnan GA. Topography and temporal evolution of hypoxic viable tissue identifed by 18F-fuoromisonidazole positron emission tomography in humans after ischemic stroke. Stroke 2003; 34: 2646-52.
23. Schellinger PD, Fiebach JB, Jansen O, Ringleb PA, Mohr A, Steiner T, Heiland S, Schwab S, Pohlers O, Ryssel H, Orakcioglu B, Sartor K, Hacke W. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann Neurol 2001; 49: 460-9.
24. Yoo AJ, Chaudhry ZA, Nogueira RG, Lev MH, Schaefer PW, Schwamm LH, Hirsch JA, Gonzalez RG. Infarct volume is a pivotal biomarker after intra-arterial stroke therapy. Stroke 2012; 43: 1323-30.
25. Denti L, Scoditti U, Tonelli C, Saccavini M, Caminiti C, Valcavi R, Benatti M, Ceda GP. The poor outcome of ischemic stroke in very old people: a cohort study of its determinants. J Am Geriatr Soc 2010; 58: 12-7.
26. Fonarow GC, Saver JL, Smith EE, Broderick JP, Kleindorfer DO, Sacco RL, Pan W, Olson DM, Hernandez AF, Peterson ED, Schwamm LH. Relationship of national institutes of health stroke scale to 30-day mortality in medicare benefciaries with acute ischemic stroke. J Am Heart Assoc 2012; 1: 42-50.
27. Ebinger M, Christensen S, De Silva DA, Parsons MW, Levi CR, Butcher KS, Bladin CF, Barber PA, Donnan GA, Davis SM; Echoplanar Imaging Thrombolytic Evaluation Trial Investigators. Expediting MRI-based proof-of-concept stroke trials using an earlier imaging end point. Stroke 2009; 40: 1353-8.
28. Saver JL, Levine SR. Alteplase for ischaemic stroke--much sooner is much better. Lancet 2010; 375: 1667-1668.
29. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC, Jr., Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-74.
30. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous al-teplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-703.
31. Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, Yang S, Hong JS. Valproate pretreat-ment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary mid-brain cultures: role of microglia. Brain Res Mol Brain Res 2005; 134: 162-9.
32. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, Wilson B, Lu RB, Gean PW, Chuang DM, Hong JS. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006; 11: 1116-25.
33. Kim HJ, Leeds P, Chuang DM. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem 2009; 110: 1226-40.
34. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Ch-uang DM. The mood stabilizers lithium and val-proate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 2009; 14: 51-9.